ARTICLE | Company News
ActivBiotics infectious news
April 7, 2008 7:00 AM UTC
ActivBiotics completed the sale of its IP covering rifalazil, antibacterial NCEs and superoxide dismutase small molecule mimetics to an undisclosed buyer for $3.5 million. The company sold its fixed ...